Chronic Hand Eczema Market Expected to rise by 2034, LEO Pharma, Japan Tobacco, Asana Biosciences, expected to drive market expansion | DelveInsight

The Chronic Hand Eczema market growth is driven by factors like increase in the prevalence of Chronic Hand Eczema, investments in research and development, entry of emerging therapies during the study period 2020-2034.
The Chronic Hand Eczema market report [https://www.delveinsight.com/report-store/chronic-hand-eczema-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] also offers comprehensive insights into the Chronic Hand Eczema market size, share, Chronic Hand Eczema epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Chronic Hand Eczema market size growth forward.

Some of the key highlights from the Chronic Hand Eczema Market Insights Report:

*
Several key pharmaceutical companies, including LEO Pharma, Japan Tobacco, Asana Biosciences, and others, are developing novel products to improve the Chronic Hand Eczema treatment outlook.

*
According to DelveInsight, the chronic hand eczema market is expected to undergo significant changes during the forecast period (2024-2034), driven by advancements in medical research and technology, better diagnostic tools, and the introduction of new therapies.

*
In September, 2024, LEO Pharma Inc. made two important announcements. First, the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for delgocitinib cream 20 mg/g (2%) as a treatment for adults with moderate to severe Chronic Hand Eczema (CHE), particularly for those who have not responded to or cannot use topical corticosteroids.

*
In September 2024, LEO Pharma A/S announced that the European Commission (EC) granted marketing authorization for Anzupgo Registered (delgocitinib) cream. This approval provides a new treatment option for adult patients with moderate to severe CHE in Europe, particularly where traditional corticosteroid treatments have proven ineffective. These announcements underscore LEO Pharma's continued leadership in dermatological care and represent a significant step forward in improving treatment options for chronic hand eczema patients.

*
In 2023, the total market size for chronic hand eczema in the United States was approximately USD 431 million. Among the EU4 countries and the UK, Germany had the largest market size at around USD 71 million, followed by France and the UK with approximately USD 46 million and USD 45 million, respectively.

*
In the EU4 countries and the UK, Germany had the highest number of chronic hand eczema cases, with nearly 493,000, followed by France and the UK with approximately 321,000 and 317,000 cases, respectively. In the US, nearly 1 million cases were diagnosed, and this number is projected to increase by 2034 due to environmental factors like weather conditions, and lifestyle factors such as stress and poor skincare habits.

*
Chronic hand eczema affects females more than males, primarily due to exposure to irritants from household and skincare products. In 2023, there were around 1 million females and 993,000 males with the condition in the US.

*
In the UK, cases of chronic hand eczema in 2023 were distributed across age groups as follows: approximately 52,000 cases in those aged 20-29 years, 98,000 in those aged 30-49 years, 29,000 in those aged 50-69 years, and 26,000 in those aged 70 and above.

*
In Japan, chronic hand eczema represented approximately 15% of global cases in 2023. Among various subtypes, irritant contact eczema was the most prevalent, accounting for around 27% of cases, while fingertip eczema had the lowest prevalence at about 4%. These cases are expected to increase by 2034, driven by modern lifestyle factors such as high stress, poor dietary habits, and sedentary behavior, which worsen inflammatory conditions like eczema in Japan.

*
Companies involved in chronic hand eczema treatment development, including Regeneron, Sanofi, Stiefel Laboratories, and Asana Biosciences, are exploring potential treatments that could be launched during the forecast period (2024-2034).

Strategise your business goals by understanding market dynamics @ Chronic Hand Eczema Market Landscape [https://www.delveinsight.com/sample-request/chronic-hand-eczema-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Chronic Hand Eczema Overview

Chronic hand eczema is a common inflammatory skin condition marked by dry, red, itchy, and often painful patches on the hands. It can occur in cycles of flare-ups and remissions or persist continuously. Causes include genetic factors, environmental triggers like irritants and allergens, frequent handwashing, and stress. The condition can severely impact daily life, leading to both physical discomfort and emotional distress.

Diagnosis is made through a thorough medical history, physical skin examination, and sometimes additional tests. Doctors assess symptoms, skin appearance, and possible triggers related to lifestyle or work. Patch testing may be performed to identify allergens, and other skin conditions like psoriasis, fungal infections, or contact dermatitis may be ruled out. Accurate diagnosis helps in developing a personalized treatment plan for better management of the disease.

Do you know the treatment paradigms for different countries? Download our Chronic Hand Eczema Market Sample Report [https://www.delveinsight.com/report-store/chronic-hand-eczema-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Chronic Hand Eczema Epidemiology Segmentation

DelveInsight's Chronic Hand Eczema market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Chronic Hand Eczema historical patient pools and forecasted Chronic Hand Eczema patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Chronic Hand Eczema Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:

*
Chronic Hand Eczema Prevalence

*
Age-Specific Chronic Hand Eczema Prevalence

*
Gender-Specific Chronic Hand Eczema Prevalence

*
Diagnosed and Treatable Cases of Chronic Hand Eczema

Visit for more @ Chronic Hand Eczema Epidemiological Insights [https://www.delveinsight.com/report-store/chronic-hand-eczema-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Chronic Hand Eczema Market Insights

Several types of medications are commonly used to manage chronic hand eczema. Topical corticosteroids are the first-line treatment, helping to reduce inflammation, itching, and swelling during flare-ups, though they are generally used short-term to avoid side effects like skin thinning. Topical calcineurin inhibitors (such as tacrolimus and pimecrolimus) are effective alternatives, especially for sensitive areas like the hands and face, as they work by calming the skin's immune response.

Emollients and moisturizers are crucial for daily care, helping to repair the skin barrier, lock in moisture, and prevent irritation and flare-ups. Topical immunomodulators like crisaborole are also used to control inflammation, particularly when corticosteroids or calcineurin inhibitors are unsuitable or ineffective. These treatments are often combined for a more effective, tailored approach to managing the condition.

Chronic Hand Eczema Market Outlook

Current management of chronic hand eczema primarily relies on topical treatments, including corticosteroids, calcineurin inhibitors, and moisturizers, to alleviate symptoms, control inflammation, and repair the skin barrier. For more severe cases, systemic options like oral medications or biologic therapies may be considered. The chronic hand eczema treatment market is steadily advancing, driven by improved medical understanding, the introduction of new therapies, shifting patient expectations, increased awareness among healthcare providers and patients, and the impact of environmental and lifestyle changes.

Chronic Hand Eczema Marketed Drugs

*
TOCTINO (alitretinoin): Basilea Pharmaceutica/ Stiefel Laboratories

Chronic Hand Eczema Emerging Drugs

*
ARQ-252: Arcutis Biotherapeutics

*
Delgocitinib: LEO Pharma/Japan Tobacco

Chronic Hand Eczema Key Companies

*
LEO Pharma

*
Japan Tobacco

*
Asana Biosciences

*
And others

For more information, visit Chronic Hand Eczema Market Analysis, Patient Pool, and Emerging Therapies [https://www.delveinsight.com/sample-request/chronic-hand-eczema-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Scope of the Chronic Hand Eczema Market Report:

*
11 Years Forecast

*
7MM Coverage

*
Descriptive overview of Chronic Hand Eczema, causes, signs and symptoms, diagnosis, treatment

*
Comprehensive insight into Chronic Hand Eczema epidemiology in the 7MM

*
Chronic Hand Eczema marketed and emerging therapies

*
Chronic Hand Eczema companies

*
Chronic Hand Eczema market drivers and barriers

Table of Contents:

1 Chronic Hand Eczema Market Key Comprehensive Insights

2 Chronic Hand Eczema Market Report Introduction

3 Competitive Intelligence Analysis for Chronic Hand Eczema

4 Chronic Hand Eczema Market Analysis Overview at a Glance

5 Executive Summary of Chronic Hand Eczema

6 Chronic Hand Eczema Epidemiology and Market Methodology

7 Chronic Hand Eczema Epidemiology and Patient Population

8 Chronic Hand Eczema Patient Journey

9 Chronic Hand Eczema Treatment Algorithm, Chronic Hand Eczema Current Treatment, and Medical Practices

10 Key Endpoints in Chronic Hand Eczema Clinical Trials

11 Chronic Hand Eczema Marketed Therapies

12 Chronic Hand Eczema Emerging Therapies

13 Chronic Hand Eczema: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Chronic Hand Eczema

16 Chronic Hand Eczema Market Key Opinion Leaders Reviews

18 Chronic Hand Eczema Market Drivers

19 Chronic Hand Eczema Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Chronic Hand Eczema Epidemiology 2034

DelveInsight's "Chronic Hand Eczema - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Chronic Hand Eczema epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Chronic Hand Eczema Pipeline 2024

"Chronic Hand Eczema Pipeline Insights, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Chronic Hand Eczema market. A detailed picture of the Chronic Hand Eczema pipeline landscape is provided, which includes the disease overview and Chronic Hand Eczema treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=chronic-hand-eczema-market-expected-to-rise-by-2034-leo-pharma-japan-tobacco-asana-biosciences-expected-to-drive-market-expansion-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.